Biocontrol Technology
This article was originally published in The Gray Sheet
Executive Summary
FDA will purchase one of the firm's Diasensor 1000 noninvasive blood glucose monitors, as the agency looks to "gain knowledge of the performance of such devices over their full range of performance," the company reports Feb. 9. The firm says it plans to "conduct a seminar to educate the FDA staff on the use and maintenance of this particular instrument so they can evaluate its performance characteristics and conduct laboratory research on noninvasive monitoring." Biocontrol has not yet resubmitted its 510(k) for the system since FDA's decision to withhold approval until further data on home use is collected
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.